Dacarbazine citrate 是一种细胞周期非特异性抗肿瘤烷基化剂。Dacarbazine citrate 抑制 T 和 B 淋巴细胞反应，IC50分别为 50 和 10 μg/mL。Dacarbazine citrate 可用于凋亡和多种癌症如转移性恶性黑色素瘤的研究。
| 生物活性 | Dacarbazine citrate is a cell cycle nonspecificantineoplasticalkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, withIC50values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research ofapoptosisand various cancers such as metastatic malignant melanoma[1][2]. |
体外研究
(In Vitro) | Dacarbazine citrate has less pronounced inhibition of mitogenesis with IC50values of 50 and 10 μg/mL for T and B cells, respectively[2].
Dacarbazine citrate (30 μM, 0-14 min) evokes a concentration-dependent calcium response in hTRPA1-HEK293 cells with an EC50value of 23 μM and selectively activates the human TRPA1 channel[3].
Dacarbazine citrate (100-10,000 μM, 24 h) has cytotoxic action on B16-F10 melanoma cells[3].
Cell Viability Assay[3] | Cell Line: | B16-F10 cell | | Concentration: | 100-10,000 μM | | Incubation Time: | 24 h | | Result: | Reduced cell viability to 3,000 and 10,000 uM, with an inhibition percentage of 62 ± 2% after 24 h of incubation. |
|
体内研究
(In Vivo) | Dacarbazine citrate (1 mg/kg, i.p.) evokes a concentration-dependent calcium response and the maximum calcium response with an EC50value of 16 μM in a subset of cells of cultured mouse DRG neurons and excites TRPA1 in rodent sensory neurons[3].
Dacarbazine citrate (1 mg/kg, i.p.; 1, 3, 5 and 7 days for chronic pain or 1 mg/kg, i.p. for acute treatment) induces mechanical and cold allodynia in mice[3].
Dacarbazine citrate-induced nociception can be reduced by TRPA1-deficient mice and antisense oligonucleotide for the TRPA1 receptor[3].
Dacarbazine citrate-induced chronic nociception can be reduced by selective TRPA1 receptor antagonists and antioxidants[3].
Dacarbazine citrate-induced nociception can be resisted by RPA1 antagonist or an antioxidant in a tumor-associated cancer pain model[3].
| Animal Model: | C57BL/6, Trpa1+/+or Trpa1–/–mice[3] | | Dosage: | 1 mg/kg | | Administration: | 1 mg/kg, i.p. (for acute treatment);
1 mg/kg, i.p.; 1, 3, 5 and 7 days (for chronic pain) | | Result: | Caused mechanical allodynia with acute or repeated administration. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com